LSV Asset Management Has $3.28 Million Stake in Illumina, Inc. $ILMN

LSV Asset Management boosted its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 22.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 25,000 shares of the life sciences company’s stock after acquiring an additional 4,600 shares during the period. LSV Asset Management’s holdings in Illumina were worth $3,279,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Capital World Investors lifted its position in Illumina by 20.0% during the 3rd quarter. Capital World Investors now owns 19,976,850 shares of the life sciences company’s stock worth $1,897,178,000 after acquiring an additional 3,331,542 shares during the last quarter. State Street Corp increased its holdings in shares of Illumina by 6.8% during the 3rd quarter. State Street Corp now owns 5,999,790 shares of the life sciences company’s stock worth $569,800,000 after purchasing an additional 382,520 shares during the period. AQR Capital Management LLC increased its holdings in shares of Illumina by 3.1% during the 3rd quarter. AQR Capital Management LLC now owns 3,398,027 shares of the life sciences company’s stock worth $315,915,000 after purchasing an additional 102,147 shares during the period. Bank of America Corp DE increased its holdings in shares of Illumina by 1.9% during the 2nd quarter. Bank of America Corp DE now owns 1,930,843 shares of the life sciences company’s stock worth $184,222,000 after purchasing an additional 35,167 shares during the period. Finally, ARK Investment Management LLC increased its holdings in shares of Illumina by 25.7% during the 3rd quarter. ARK Investment Management LLC now owns 1,467,879 shares of the life sciences company’s stock worth $139,405,000 after purchasing an additional 299,801 shares during the period. Institutional investors and hedge funds own 89.42% of the company’s stock.

Analyst Ratings Changes

ILMN has been the topic of several research reports. Daiwa Securities Group upgraded shares of Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 price objective on the stock in a report on Thursday, May 14th. Robert W. Baird set a $137.00 price objective on shares of Illumina in a report on Friday, February 6th. JPMorgan Chase & Co. boosted their price objective on shares of Illumina from $120.00 to $125.00 and gave the stock a “neutral” rating in a report on Friday, May 1st. Canaccord Genuity Group dropped their price objective on shares of Illumina from $150.00 to $140.00 and set a “hold” rating on the stock in a report on Friday, May 1st. Finally, Royal Bank Of Canada initiated coverage on shares of Illumina in a report on Thursday, May 14th. They set an “outperform” rating and a $170.00 price objective on the stock. Seven investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $137.75.

Insider Transactions at Illumina

In related news, SVP Christensen Jakob Wedel sold 700 shares of the company’s stock in a transaction dated Wednesday, May 6th. The shares were sold at an average price of $139.04, for a total value of $97,328.00. Following the sale, the senior vice president owned 15,056 shares of the company’s stock, valued at $2,093,386.24. The trade was a 4.44% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 104,393 shares of the company’s stock in a transaction dated Thursday, May 14th. The shares were sold at an average price of $145.34, for a total transaction of $15,172,478.62. Following the completion of the sale, the director directly owned 3,500,048 shares in the company, valued at approximately $508,696,976.32. The trade was a 2.90% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 330,160 shares of company stock worth $48,028,308. 2.90% of the stock is currently owned by insiders.

Illumina Stock Performance

NASDAQ ILMN opened at $145.23 on Wednesday. The stock has a market cap of $21.97 billion, a P/E ratio of 26.41, a PEG ratio of 2.39 and a beta of 1.42. The company’s 50-day simple moving average is $131.55 and its 200 day simple moving average is $131.34. Illumina, Inc. has a twelve month low of $78.79 and a twelve month high of $155.53. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.56.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share for the quarter, beating analysts’ consensus estimates of $1.05 by $0.10. The business had revenue of $1.09 billion for the quarter, compared to analysts’ expectations of $1.07 billion. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The firm’s revenue for the quarter was up 4.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.97 earnings per share. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. As a group, research analysts forecast that Illumina, Inc. will post 5.2 earnings per share for the current fiscal year.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.